Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Boosted by Independent Advisor Alliance

Key Points

• Independent Advisor Alliance has increased its holdings in Regeneron Pharmaceuticals by 98.7%, now owning 950 shares valued at approximately $603,000.
• Regeneron reported a quarterly EPS of $12.89, surpassing estimates significantly, alongside a revenue of $3.68 billion, a 3.6% increase year-over-year.
• The company announced a quarterly dividend of $0.88, with a payout ratio of 8.87%, solidifying its commitment to returning value to shareholders.

Independent Advisor Alliance increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 98.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 950 shares of the biopharmaceutical company's stock after purchasing an additional 472 shares during the quarter. Independent Advisor Alliance's holdings in Regeneron Pharmaceuticals were worth $603,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Marietta Wealth Management LLC grew its holdings in Regeneron Pharmaceuticals by 30.2% during the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock worth $6,836,000 after acquiring an additional 2,501 shares during the period. GAMMA Investing LLC grew its holdings in Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after acquiring an additional 814,713 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Regeneron Pharmaceuticals by 3.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock worth $16,255,000 after acquiring an additional 955 shares during the period. KBC Group NV grew its holdings in Regeneron Pharmaceuticals by 9.4% during the first quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock worth $94,779,000 after acquiring an additional 12,793 shares during the period. Finally, Lmcg Investments LLC grew its holdings in Regeneron Pharmaceuticals by 231.3% during the first quarter. Lmcg Investments LLC now owns 14,481 shares of the biopharmaceutical company's stock worth $9,184,000 after acquiring an additional 10,110 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 0.8%

Shares of NASDAQ REGN opened at $565.97 on Friday. The stock has a market cap of $59.99 billion, a price-to-earnings ratio of 14.26, a PEG ratio of 1.90 and a beta of 0.33. The business has a 50 day simple moving average of $542.46 and a 200 day simple moving average of $596.26. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The business had revenue of $3,675,600 billion during the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter in the previous year, the business posted $11.56 EPS. The firm's quarterly revenue was up 3.6% compared to the same quarter last year. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a report on Monday. Citigroup reaffirmed a "buy" rating and set a $650.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Royal Bank Of Canada lifted their target price on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a report on Monday, August 4th. The Goldman Sachs Group dropped their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Finally, Robert W. Baird dropped their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research note on Friday, April 25th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $838.00.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.